CNS Pharmaceuticals (CNSP) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CNS Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | SKYE |
|---|---|---|
| Share price | $5.35 | $1.68 |
| Market cap | $7.82M | $7.44M |
| 1-day change | -1.47% | +1.82% |
| EPS (TTM) | $-17.64 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $14.08 |
| 52-week low | $1.90 | $1.50 |
| Distance from 52-week high | -49.24% | -88.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.92% | +3947.62% |
| Average volume | 6.40K | 89.28K |
| Shares outstanding | 1.46M | 4.43M |
| Employees | 8 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
CNSP vs SKYE FAQ
Which is bigger, CNS Pharmaceuticals or Skye Bioscience?
CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $7.82M compared with $7.44M for Skye Bioscience (SKYE).
Are CNS Pharmaceuticals and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.